Annexon Inc   (ANNX)
Other Ticker:  
Price: $5.1150 $-0.63 -10.889%
Day's High: $5.7 Week Perf: -17.1 %
Day's Low: $ 5.11 30 Day Perf: -11.35 %
Volume (M): 1,345 52 Wk High: $ 8.26
Volume (M$): $ 6,880 52 Wk Avg: $3.81
Open: $5.54 52 Wk Low: $1.57

 Market Capitalization (Millions $) 385
 Shares Outstanding (Millions) 75
 Employees 52
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -141
 Cash Flow (TTM) (Millions $) -143
 Capital Exp. (TTM) (Millions $) 0

Annexon Inc
Annexon Inc is a biopharmaceutical company that is focused on developing therapies for patients with autoimmune and neurodegenerative diseases. The company was founded in 2011 in South San Francisco, California, and has since expanded operations and staff to multiple locations, including Brisbane, California, and New Haven, Connecticut.

The company's research efforts are centered around a unique approach to treating autoimmune and neurodegenerative disorders by targeting the complement pathway, which is a key part of the immune system that plays a critical role in fighting infections and maintaining tissue homeostasis. Dysregulation of the complement pathway has been linked to a variety of diseases, including multiple sclerosis, Alzheimer's disease, and Parkinson's disease. Annexon's focus is on developing therapies that carefully modulate this pathway to restore balance and halt disease progression.

One of the company's most promising drug candidates is ANX005, which is being developed for the treatment of complement-mediated autoimmune and neurodegenerative diseases. ANX005 is designed to specifically target the C1q protein, which is a key regulator of the complement pathway.

Annexon has received significant funding from both venture capital firms and pharmaceutical companies. The company raised $75 million in a Series C funding round in 2020 and has secured partnerships with several top-tier companies in the biopharmaceutical industry, including Biogen and Takeda.

The company's leadership team includes a number of industry veterans with extensive experience in drug development and biotechnology. CEO Doug Love was formerly the COO of Rigel Pharmaceuticals, while Chief Scientific Officer Ben Barres was a renowned neuroscientist and professor at Stanford University prior to joining Annexon.

Overall, Annexon Inc is a fast-growing biopharmaceutical company with a promising pipeline of drug candidates and a unique approach to treating complex diseases. With strong funding, partnerships, and leadership, the company is well positioned to continue making significant contributions to the field of medicine.

   Company Address: 1400 Sierra Point Parkway Brisbane 94005 CA
   Company Phone Number: 822-5500   Stock Exchange / Ticker: NASDAQ ANNX


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report


Annexon's Continued Growth: Attracting Talent and Securing Success in the Biopharmaceutical Industry

Published Tue, Apr 16 2024 8:05 PM UTC

Annexon Continues to Attract Talent with Inducement Grants for New Employees: A Positive Sign for Investors
Annexon, Inc. (Nasdaq: ANNX), a leading biopharmaceutical company focused on developing innovative complement-based therapies for individuals suffering from inflammatory-related diseases, has recently announced the granting of inducement awards to two new non-execu...

Product Service News

Annexon Grants Inducement Award to New Employee as Part of Employment Inducement Plan

Published Mon, Mar 18 2024 8:05 PM UTC

Annexon, Inc., a renowned clinical-stage biopharmaceutical company, recently made an exciting announcement regarding the grant of an inducement award to a new non-executive employee. Under the provisions of the 2022 Employment Inducement Award Plan, the equity award was officially approved on March 15, 2024, in accordance with the Nasdaq Listing Rule 5635(c)(4).Annexon, Inc....


Annexon Inc. Grants Inducement to New Employee, Augmenting Shareholder Value

Published Tue, Feb 20 2024 9:05 PM UTC

Brisbane, Calif. - Annexon, Inc., a clinical-stage biopharmaceutical company focused on developing complement-based medicines for individuals battling severe inflammatory-related diseases, recently announced the awarding of an equity grant to a new non-executive employee under the provisions of the 2022 Employment Inducement Award Plan. This strategic move showcase...

Product Service News

Annexon Outlines 2024 Priorities with Late-Stage Clinical Milestones Across Upstream Complement Portfolio for Autoimmune, Ophthalmic and Neurodegenerative Diseases

Published Mon, Jan 8 2024 1:00 AM UTC

In a recent breakthrough, Annexon, a renowned biopharmaceutical company, has meticulously delineated its priorities for the year 2024, pivoting towards the milestone of late-stage clinical trials across its upstream complement portfolio. The portfolio comprises an array of groundbreaking treatments for autoimmune, ophthalmic, and neurodegenerative diseases. This revolutionar...


Annexon, Inc. Secures Substantial Funding Through Successful Public Offering, Paving the Way for Revolutionary Complement Medicines.

Published Wed, Dec 20 2023 10:28 PM UTC

Annexon, Inc. Announces Successful Pricing of Public Offering, Strengthening Its Position in the Biopharmaceutical Industry
Brisbane, Calif. - Annexon, Inc. (NASDAQ: ANNX), a leading clinical-stage biopharmaceutical company specializing in the development of cutting-edge complement medicines for patients suffering from classical complement-mediated autoimmune, neurodegen...



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com